Phase III Clinical Trials in Argentina

Clinical Trials in: Mexico, Argentina, Colombia and Brazil.

Locally-Based, Full Service CRO

Contact us today to learn more.

+ 0
Sites Throughout LATAM
+ 200
Patients in our network
+ 0
Conducted Studies
0 %
Lost-to-Follow Up rate
As a leading CRO in LATAM, we specialize in supporting clinical trials throughout the region. Our extensive experience and broad network of clinical sites enable us to execute trials with speed and efficiency, ensuring high patient recruitment and retention rates.

Phase III Clinical Trials in Argentina

Phase III Clinical Trials in Argentina – Clinical Trials in LATAM

Clinical trials, particularly Phase III trials, are essential stages in the development and evaluation of new medical treatments and therapies. In Argentina, these trials play a critical role in assessing the safety and efficacy of experimental drugs and medical devices before potential approval and widespread use.

In this blog, we will explore the significance of Phase III clinical trials in Argentina, the country’s regulatory framework, recent advancements, and the opportunities they offer for patients and the healthcare industry.

Understanding Phase III Clinical Trials

Phase III clinical trials represent the final and crucial phase of the drug development process. At this stage, the experimental treatment is tested on a larger group of patients to gather comprehensive data on its safety, effectiveness, and potential side effects. The results from Phase III trials are pivotal in determining whether a drug or medical device can be considered for regulatory approval and market launch.

Regulatory Framework in Argentina

In Argentina, the regulation of clinical trials is overseen by the National Administration of Drugs, Food, and Medical Devices (ANMAT). ANMAT ensures that all clinical trials conducted in the country adhere to ethical guidelines, international standards, and Good Clinical Practice (GCP) principles.

The regulatory framework in Argentina has been refined over the years to create a more efficient and supportive environment for clinical research. This has contributed to Argentina’s emergence as a preferred destination for Phase III clinical trials.

Advancements in Phase III Clinical Trials in Argentina

  1. Leading Research Infrastructure

Argentina boasts a well-established and modern research infrastructure with numerous research centers, hospitals, and academic institutions dedicated to clinical research. The country’s investment in research and development has attracted experienced investigators, fostering a conducive environment for successful clinical trial implementation.

  1. Diverse and Representative Patient Pool

Argentina’s population is ethnically diverse, presenting a unique advantage for clinical trials. The diversity allows for a more representative patient pool, ensuring that trial results are applicable to different populations and can be generalized on a global scale.

  1. International Recognition and Collaboration

Argentina’s commitment to advancing medical research has earned it international recognition in the field of clinical trials. This recognition has led to increased collaborations between Argentine research centers and international pharmaceutical companies and organizations. The exchange of expertise and resources benefits both parties and facilitates the successful execution of complex trials.

Phase III Clinical Trials in Argentina

Phase III Clinical Trials in Argentina

Phase III Clinical Trials in Argentina

Opportunities for Patients

Participating in Phase III clinical trials in Argentina offers several opportunities for patients:

  1. Early Access to Innovative Therapies

Clinical trials provide patients with early access to promising treatments that may not yet be available in the market. For patients with serious or rare medical conditions, participation in a clinical trial can be a lifeline, offering hope for improved health outcomes.

  1. Comprehensive Medical Care and Monitoring

Throughout the trial, patients receive comprehensive medical care and close monitoring from experienced healthcare professionals. This level of care ensures the safety and well-being of participants during their involvement in the trial.

  1. Contributing to Medical Advancements

By participating in Phase III clinical trials, patients actively contribute to advancing medical knowledge and the development of new therapies. Their involvement in clinical research plays a significant role in shaping future healthcare practices and patient care.

Opportunities for the Healthcare Industry

Conducting Phase III clinical trials in Argentina presents various advantages for the healthcare industry:

  1. Cost-Effectiveness

Argentina offers a cost-effective environment for conducting clinical trials compared to some other regions. This cost-efficiency allows sponsors to allocate resources efficiently and invest in further research and development.

  1. Efficient Patient Recruitment

The country’s diverse and willing patient population streamlines patient recruitment, potentially reducing the time required to complete the trial. Faster enrollment can accelerate the overall drug development process and bring innovative treatments to market sooner.

  1. Favorable Regulatory Environment

ANMAT’s commitment to promoting and supporting clinical research has created a favorable regulatory environment for conducting trials in Argentina. The streamlined regulatory processes facilitate the initiation and completion of trials, contributing to their overall success.


Phase III clinical trials in Argentina are playing a pivotal role in advancing medical science and improving healthcare outcomes. With a robust regulatory framework, leading research infrastructure, and a diverse patient population, Argentina offers an ideal environment for conducting Phase III trials.

Patients who participate in these trials gain early access to innovative treatments and contribute to the advancement of medical knowledge. Simultaneously, the healthcare industry benefits from Argentina’s cost-effectiveness, efficient patient recruitment, and collaborative opportunities.

As Argentina continues to solidify its position as a hub for clinical research, the nation’s contributions to medical advancements will undoubtedly shape the future of healthcare for the better, benefiting patients not only in Argentina but around the world.

Phase III Clinical Trials in Argentina

Source: World Courier

Welcome to Cohortias!

of Latin America

Simplify Your Clinical Trials with Our Expert Infrastructure in Latin America

Say goodbye to the complex, costly, and disorganized process of conducting clinical trials. Our infrastructure in Latin America streamlines the launch of studies and ensures adherence to international standards. Schedule a call with us today to discover the path to simplified clinical research in Latin America.

Phase III Clinical Trials in Argentina

Explore What We Are Doing Better

We define ourselves as a unique team, capable of blending our academic background with a global business mindset to bring the highest standard of quality and operational excellence into clinical research in Latin America.

Early Phase Trials

- First-in-Human Studies.
- Get to patients faster, no IND necessary.
- Valid data for FDA submission.

Rescue Studies

- Regain lost time and boost patient recruitment.
- We work alongside Global CROs to get studies back on track.
- More than 200 sites available.

Phase II & III Trials

- Full-Service Clinical Outsourcing.
- Proven infrastructure that can handle any trial.
- Local Regulatory Experts
- Wide network of sites and physicians.

Medical Devices

- A fast-track platform that will meet your timeline.
- We take care of everything, from shipping requirements all the way to data collection.
Phase III Clinical Trials in Argentina

Full Service CRO in LATAM

Outsourcing Clinical Trials to Latin America

Unlock the advantages and opportunities of outsourcing clinical trials to Latin America. Diverse patient population, streamlined regulations, and cost-effectiveness

Lower Operating Costs

From lower labor costs to lower costs for rent, utilities, and equipment, you can save money on your clinical trial budget while still ensuring the quality of your trial

Access to Emerging Markets

Latin America offers access to emerging markets, providing an opportunity for pharmaceutical companies to expand their reach and reach new patient populations.

Phase III Clinical Trials in Argentina

Cohortias is redefining Clinical Research in Latin America

We are committed to become leaders in providing clinical research services in Latin America. Here at Cohortias, we combine our academic roots, proven experience and a large pool of patients from an extensive network of sites.

Our main purpose is to deliver high quality data.

Phase III Clinical Trials in Argentina

Clinical Research in Latin America

Cohortias has built an extensive and highly reputable network of clinical sites which can access patients in a timely manner and operate within a standard-of-care comparable to the U.S. healthcare system.


  • Site Management

  • Data Management

  • Site Selection

  • Regulatory Submissions

  • Clinical Monitoring

  • Protocol Development


Beta Trials Platform

  • First-in-human studies

Medical Devices

  • Pilot and Pivotal Device Studies

Phases I – III

  • We partner with our clients to bring their products in a fast and efficient manner to the market with the highest quality standards


  • Diabetes/Metabolic Syndromes
  • Infectious Diseases
  • Cardiovascular
  • Neurology
  • Respiratory
  • Oncology

Phase III Clinical Trials in Argentina

Clinical Research in Latin America

Academic Leadership and Extensive Clinical Site Network for Efficient Clinical Trials

  • Our peer-to-peer management approach guarantees high patient recruitment and retention in any clinical trial

High Speed Execution

  • We offer the quickest start-up times in each country.
  • Efficient Clinical Site Selection and Contracting.
  • Benefit from our extensive network of clinical sites and streamlined contracting process.

Operational Excellence

  • Proven record of delivering rescue studies, we consistently exceed industry performance standards.
  • Our team provides efficient query resolution to keep your trial on track.

Business Insight and Flexibility

  • We offer innovative pricing models and short lines of communication to ensure maximum flexibility and cost-effectiveness.
  • At Cohortias, we prioritize  short lines of communication to ensure efficient collaboration.
  • Swift adaptation to changes in the trial landscape to keep your study on schedule.

Phase III Clinical Trials in Argentina

We provide our services with offices in:

Colombia &

Daniela Maresca
Daniela Maresca | Country Lead Argentina
Martín Hernández-Torre | CMO
Maritza Rojas | CRA II
Pedro Alvarez | Business Development Manager
Samantha Rodriguez Cohortias
Samantha Rdz. | Start-Up Manager
Phase III Clinical Trials in Argentina

The Cohortias Team

Phase III Clinical Trials in Argentina

As the largest South American Contract research Organization, we know the Advantages and Challenges Of the Region

Let Us Guide You Through The Latin American Clinical Research Landscape

Phase III Clinical Trials in Argentina

Network & Partnerships